A Comparison of Bone Marrow Derived and Adipose Derived Stem Cells in Point of Care Goat Non-Instrumented Posterolateral Intertransverse Spinal Fusion Daria Brigitte Neidre, Ph.D. The University of Texas at Austin, May, 2010 Supervisor: Roger P. Farrar Concentrated bone marrow containing mesenchymal stem cells (BMSCs) in combination with osteoconductive scaffolds has been used in orthopaedics to replace the need for iliac crest bone grafts. Autologous BMSC volume is limited, but adipose tissue represents a large reservoir of stem cells; adipose derived stem cells (ADSCs). To test these cells, a large animal model using goats was selected due to their similarities to humans in loading conditions of the spine, trabecular bone structure of the vertebrae, and their common use in testing orthopaedic therapies as a clinically relevant model. The aim of this study is to characterize cell surface markers of the isolated cells through flow cytometry, compare goat BMSCs and ADSCs using multilineage differentiation into the osteogenic and adipogenic lineages, and utilize them in a “Point-of-Care” non-instrumented posterolateral lumbar spinal fusion. Both BMSCs and ADSCs were confirmed as stem cells through lack of expression of markers CD34, CD45, CD90, and CD105, which is supported by literature. Both cell types also differentiated into both the adipogenic and osteogenic lineages. Although we had positive in vitro results, we had limited in vivo results. There were no differences between BMSCs, ADSCs and control implantation in identifiable spinal fusion at 3 or 6 months through radiographs or CT scans. Additionally, there were no differences between groups at 6 months in biomechanical testing, histology and microradiographs. Although our in vivo results were lacking in demonstrating fusion at 6 months, this study is the first of it’s kind to investigate a large animal model comparison of BMSCs and ADSCs in spinal fusion and demonstrated that “Point-of-Care” stem cells derived from either bone marrow or adipose tissue demonstrated the potential for bone formation. The in vivo results suggests that this model can be used for stem cell research in orthopaedics, but further research needs to be performed to determine their use, proper scaffold and potential osteoinductive materials needed for solid fusion results in the in vivo model. / text

Background: Stem cell therapy can facilitate cardiac repair after healed myocardial infarction but the optimal cell type remains uncertain. Aims: To investigate the pathophysiology of heart failure in a canine model of healed myocardial infarction and to compare the efficacy and the safety of autologous bone marrow mononuclear cell (BMNC) transfer and mesenchymal stem cell (MSC) transfer in this model. It was a blind, randomized and placebo control study. Methods: Eleven weeks after coronary ligation, 24 dogs received intramyocardial injections of BMNC, MSC or Placebo (n = 8 per groups). Echocardiography, conductance method, magnetic resonance imaging, serum neurohormones, holter monitoring, macromorphometry, histology and real time quantitative polymerase chain reaction were used to assess cardiac performance, safety and remodelling in healthy animals, before cell transplantation and up to 16 weeks’ follow-up. Results: The model was characterized by decreased left ventricular end-systolic elastance and ventricular-arterial uncoupling without alteration of compliance. Four months after BMNC transfer, the regional systolic function measured at echocardiographic showed a sustained improvement. This improvement was associated with an improved left ventricular end-systolic elastance and a decreased infarct size. Although the left ventricular ejection fraction stayed unchanged, the serum level of N-terminal B-type natriuretic propeptide level decreased. Mononuclear cell transfer was also associated with increased left ventricular relative wall area, increased vascular density, intramyocardial vascular remodelling and upregulation of angiogenic factors gene expression. Mesenchymal stem cell transfer only improved lately and moderately the regional systolic function, without improvement of cardiac contractility or decreased infarct size. Conclusions: In a canine model of chronic myocardial infarction, BMNC transfer is superior to MSC transfer in improvement of cardiac contractility and regional systolic function, and to reduce the infarct size and plasma N-terminal B-type natriuretic propeptide level. Functional improvement is associated with a favourable angiogenic environment and neovascularization.

<p>Background: Stem cell therapy can facilitate cardiac repair after healed myocardial infarction but the optimal cell type remains uncertain. <p>Aims: To investigate the pathophysiology of heart failure in a canine model of healed myocardial infarction and to compare the efficacy and the safety of autologous bone marrow mononuclear cell (BMNC) transfer and mesenchymal stem cell (MSC) transfer in this model. It was a blind, randomized and placebo control study.<p>Methods: Eleven weeks after coronary ligation, 24 dogs received intramyocardial injections of BMNC, MSC or Placebo (n = 8 per groups). Echocardiography, conductance method, magnetic resonance imaging, serum neurohormones, holter monitoring, macromorphometry, histology and real time quantitative polymerase chain reaction were used to assess cardiac performance, safety and remodelling in healthy animals, before cell transplantation and up to 16 weeks’ follow-up. <p>Results: The model was characterized by decreased left ventricular end-systolic elastance and ventricular-arterial uncoupling without alteration of compliance. <p>Four months after BMNC transfer, the regional systolic function measured at echocardiographic showed a sustained improvement. This improvement was associated with an improved left ventricular end-systolic elastance and a decreased infarct size. Although the left ventricular ejection fraction stayed unchanged, the serum level of N-terminal B-type natriuretic propeptide level decreased. Mononuclear cell transfer was also associated with increased left ventricular relative wall area, increased vascular density, intramyocardial vascular remodelling and upregulation of angiogenic factors gene expression. Mesenchymal stem cell transfer only improved lately and moderately the regional systolic function, without improvement of cardiac contractility or decreased infarct size. <p>Conclusions: In a canine model of chronic myocardial infarction, BMNC transfer is superior to MSC transfer in improvement of cardiac contractility and regional systolic function, and to reduce the infarct size and plasma N-terminal B-type natriuretic propeptide level. Functional improvement is associated with a favourable angiogenic environment and neovascularization. <p> / Doctorat en Sciences biomédicales et pharmaceutiques / info:eu-repo/semantics/nonPublished

Peripheral nerve injuries occur with high incidence and often result in profound and permanent impact on the life of patients and on healthcare expenditure. Schwann cells (SC) play a promoting role in peripheral nerve regeneration providing physical and neurotrophic support that aids axon re-growth. However, these beneficial properties are not exploitable in nerve tissue engineering due to the difficulties in SC harvesting and expansion in culture. Adult stem cells derived from bone marrow (BM-MSC) and from adipose tissue (ASC) can be differentiated in SC-like cells and be used as SC substitutes in bioengineered nerve conduits for the improvement of peripheral nerve regeneration. Pharmacological intervention approaches for the treatment of nerve injury are still not clinically available. Nevertheless, γ-Aminobutyric acid (GABA) receptors have been recently suggested as a putative target for such purpose. GABA is the main inhibitory neurotransmitter of the adult brain and interacts with two different receptor types. However, both GABA-A and GABA-B receptor types are functionally expressed also in SC, where they are involved in the regulation of SC physiology and in the development of the peripheral nervous system (PNS).The aim of this thesis was to characterise the GABAergic system of BM-MSC and ASC differentiated into a SC-like phenotype and to evaluate changes in the expression levels following differentiation. Moreover, the effect of specific GABA receptor ligands on cell proliferation and neurotrophic potential of differentiated stem cells were assessed. Using reverse transcriptase polymerase chain reaction, western blot analysis and immunohistochemistry we demonstrated that adult stem cells express several subunits of both GABA-A and GABA-B receptor systems such as GABA-B1a, GABA-B1b and GABA-B2, as well as GABA-A α2 and GABA-A β3. Expression levels and cellular localisation were comparable with adult and neonatal SC cultures used as positive controls, and protein expression levels for some of the subunits changed following glial differentiation. Interestingly, stimulation of GABA receptors with specific agonists influenced stem cell proliferation in two opposite ways. Baclofen, a GABA-B receptor agonist decreased proliferation of SC and differentiated ASC (dASC), but not of SC-like BM-MSC (dBM-MSC). By contrast, muscimol, a GABA-A receptor agonist, increased proliferation in SC and in both dASC and dBM-MSC. This suggests that GABAergic signalling could be a potential player in the mechanisms regulating stem cell differentiation and proliferation as reported in SC. Finally, baclofen treatments on SC and dASC modulated the expression levels and the release of the neurotrophins BDNF and NGF, which are key actors in the processes involved with peripheral nerve regeneration. Although further studies will be needed to clarify the role of GABA receptors in the PNS, the presence of functional GABA receptors on SC-like adult stem cells could represent an exploitable pharmacological target to modulate stem cell physiology and improve their neurotrophic potential for peripheral nerve regeneration.

La cardiopathie ischémique incluant l’insuffisance cardiaque est la deuxième cause de mortalité annuelle au Canada. Bien que de nombreuses stratégies préventives et des thérapies pharmacologiques retardent la progression de la maladie, il n’existe aucune solution qui module directement aux les remaniements pathologiques et la perte de cardiomyocytes. Au cours des 25 dernières années, de multiples progrès dans les domaines de la médecine régénérative et de la thérapie cellulaire ont annoncé des résultats prometteurs, mais les résultats d’études cliniques contemporaines demeurent plutôt mitigés. COMPARE-AMI, une étude randomisée-contrôlée de phase II, a évalué l’effet d’injections intracoronariennes de cellules souches hématopoïétiques CD133+ chez des patients souffrant d’infarctus aigu. IMPACT-CABG, une ÉRC de phase II a également évalué l’effet d’injections intramyocardiques de cellules CD133+ chez les patients souffrant de cardiomyopathie ischémique chronique nécessitant une revascularisation chirurgicale. Nous avons émis l’hypothèse que les cellules CD133+ utilisées dans des études cliniques de cardiomyopathies ischémiques aiguës et chroniques des patients répondant à la thérapie cellulaire exhibent des signatures transcriptomiques communes responsables de leur effet thérapeutique. En classant les patients en tant que répondants et non-répondants selon leur fonction cardiaque, nous avons évalué, a posteriori, ces patrons d’expression. Les cellules CD133+ autologues de patients jugés répondants expriment des signatures qui sont hautement conservées entre elles (incluant l’angiogénèse, la régulation de la réponse au stress et la survie cellulaire) et uniques d’un modèle à l’autre et qui pourraient, en partie, exprimer les issus cliniques des patients. Afin de maximiser les effets de la thérapie cellulaire aux cellules souches, nous avons par la suite tenté de reproduire ces phénotypes par stimulation pharmacologique avec des inhibiteurs d’HSP90 pour leurs effets qui semblent reproduire ces signatures. Ainsi, nous avons démontré qu’une stimulation de cellules souches mésenchymateuses humaines (CSMh) au Célastrol (inhibiteur HSP90) pouvait répliquer certains de ces phénotypes. Notamment, des CSMh conditionnées activent des voies de signalisation de type ‘RISK’ et augmentent leur sécrétion de protéines en lien avec la réponse au stress ainsi que d’exosomes contenant des molécules impliquées dans la communication intercellulaire sans être liées à un changement de type cellulaire. De plus, les CSMh traitées semblent améliorer la guérison de plaie par activité paracrine et sont plus résistante à la sénescence oxydative. Ces résultats encourageants nous permettent d’envisager des stratégies plus poussées de pré-conditionnement cellulaire ex vivo de cellules CD133+ avant leur implantation. À terme, cela pourrait mener à une optimisation de la thérapie cellulaire afin d’en maximiser les bénéfices cliniques et d’en exploiter leur plein potentiel. / Ischemic cardiomyopathy and heart failure are the second annual cause of mortality in Canada. Despite rigorous prevention strategies and drug regimens preventing progression, no therapeutic modality can currently reverse the pathologic modifications of the disease. In the last quarter century, numerous advances in the field of regenerative medicine and cell therapy have demonstrated promising effects. COMPARE-AMI, a phase II randomized controlled trial (RCT), evaluated the effect of intracoronary injection of CD133+ cells in acute myocardial infarction following percutaneous intervention. IMPACTCABG, also a phase II RCT, evaluated the effect of intramyocardial injection of CD133+ hematopoietic stem cells in chronic ischemic cardiomyopathy at the time of surgical revascularization. That being said, we believe that the CD133+ cells used in therapy have shared transcriptomic signatures that are responsible for their clinical effects. By classifying patients into responders and non-responders according to an improvement in ejection fraction, we evaluated, a posteriori, those expression patterns. Autologous CD133+ cells of patients classified as responders expressed highly conserved transcriptomic signatures that could be responsible for the clinical outcomes of patients. Notably, these signatures were related to cardioprotective mechanisms including angiogenesis, stress response regulation and cell survival. In order to harness the full potential of stem cell therapy, we attempted to reproduce the identified phenotypes by pharmacological intervention with HSP90 inhibitors which are known to mimic some of these effets. Conditioned human mesenchymal stem cells (hMSC) activated ‘RISK’-type signaling pathways and augmented exosome and protein secretion relating to the response to cellular stress; this activation was unrelated to a switch of cell type. Furthermore, treated hMSC seemed to favour improved wound healing by paracrine activity and were more resistant to oxidative senescence. These encouraging results allow us to develop novel, more advance, strategies of ex vivo cell preconditioning before implantation, including of CD133+ cells. Ultimately, we hope that optimisation of cells through this mechanism and others will allow us to unleash the full potential of stem cell therapy.